La catena delle opzioni mostra i dati chiave delle opzioni azionarie di TScan Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per TScan Therapeutics..

TScan Therapeutics (NASDAQ:TCRX) Azioni, Catena delle Opzioni

TScan Therapeutics

THL Credit, Inc. 6.75% Notes due 2021

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

TScan Therapeutics Inc

TD Cowen analyst Bill Katz maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Buy and raises the price target from $165 to $178.

News

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Apollo Global Management, Raises Price Target to $178

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 10 years by 10.33% on an annualized basis producing an average annual return of 21.51%. Currently, Adobe has a market capitalization of $221.46 billion. 
Buying $1000 In ADBE: If an investor had bought $1000 of ADBE stock 10 years ago, it would be worth $7,016.66 today based on a price of $503.09 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730914362_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ADBE

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,000 Today

Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) has outperformed the market over the past 20 years by 5.74% on an annualized basis producing an average annual return of 14.08%. Currently, Digital Realty Trust has a market capitalization of $57.56 billion. 
Buying $1000 In DLR: If an investor had bought $1000 of DLR stock 20 years ago, it would be worth $14,055.33 today based on a price of $173.72 for DLR at the time of writing.
<h3>Digital Realty Trust's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730914357_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today

Shares of SolarEdge Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) dropped 20% to $15.06 during Wednesday&#8217;s session. Several solar stocks are trading lower following Donald Trump&#8217;s <a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">presidential election victory</a>.
The Republican Party's gains across the House and Senate signal a potential shift away from the green energy policies that have bolstered SolarEdge's business model. 
Trump's campaign commitments included reducing federal support for renewables and easing regulations on fossil fuel industries, which poses a threat to SolarEdge's growth trajectory and the broader renewable energy sector.
What To Know: Trump's proposed energy agenda includes plans to phase out green energy tax incentives, such as the Federal Investment Tax Credit (FITC), which currently provides a 30% tax credit for solar installations.
Concerns could mount among investors that if Trump repeals or scales back this incentive, it could impact demand for solar installations in the U.S., especially in states that lack their own substantial renewable energy subsidies.
SolarEdge, a leading provider of solar inverters and energy management solutions, relies heavily on the continued expansion of solar power adoption. 
With the possible withdrawal of federal tax benefits, SolarEdge could face serious headwinds, as potential customers may be deterred by higher upfront costs in the absence of tax relief, which could stall the company's momentum in a key market.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a>
Impact of Potential Tariffs and Trade Policies: Additionally, Trump's stance on tariffs poses a potential risk to SolarEdge's supply chain. Trump has floated the idea of a universal 10% tariff on all imports, and a <a href="https://www.benzinga.com/news/24/11/41737933/trump-tariff-proposed-may-cost-americans-78b-in-spending-study">possible 60% tariff</a> on Chinese goods could have direct repercussions.
SolarEdge sources some of its key components from international suppliers, particularly in Asia. If such tariffs were enacted, the costs of inverters and other equipment could rise sharply, squeezing the company's margins or forcing it to pass on these costs to consumers, further challenging its competitive positioning in the U.S. market.
What Else: Trump&#8217;s previous administration took a deregulatory approach toward environmental policy, rolling back numerous climate and emissions regulations. Given Trump's preference for traditional energy sectors, SolarEdge could see a policy landscape less supportive of renewable energy initiatives and one more favorable to fossil fuels. 
Without strong Federal backing, the solar industry may struggle to maintain its current growth, potentially impacting SolarEdge's revenue from its U.S. operations, which constitute a significant portion of its business.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41778433/s-p-500-dow-hit-record-highs-after-trump-win-fear-index-drops-20">S&amp;P 500, Dow Hit Record Highs After Trump Win; Fear Index Drops 20%</a>
<h2 class="wp-block-heading">Should I Sell My SEDG Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of SolarEdge Technologies have decreased by 78.4% in the past year. An investor who bought shares of SolarEdge Technologies at the beginning of the year would take a loss of $76.39 per share if they sold it today. The stock has fallen 17.51% over the past month, meaning an investor who bought shares on Oct. 1 would see a capital loss of $6.33.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
SEDG has a 52-week high of $103.15 and a 52-week low of $14.82.

SEDG

Why SolarEdge Technologies (SEDG) Stock Is Down 20%

TD Cowen analyst Bill Kirk maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Hold and lowers the price target from $62 to $58.

TD Cowen Maintains Hold on TPG, Lowers Price Target to $58

Goldman Sachs analyst Bruno Montanari maintains Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Buy and raises the price target from $24 to $28.

XMTR

Goldman Sachs Maintains Buy on Xometry, Raises Price Target to $28

Live On CNBC: Steve Weiss Buys CRH Public Limited Company

Sysco's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) short percent of float has fallen 15.52% since its last report. The company recently reported that it has 13.89 million shares sold short, which is 2.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sysco Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730914223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sysco has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sysco's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sysco's peer group average for short interest as a percentage of float is 4.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Sysco?

Fabrinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) short percent of float has risen 6.82% since its last report. The company recently reported that it has 1.47 million shares sold short, which is 5.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fabrinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730914218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fabrinet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fabrinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fabrinet's peer group average for short interest as a percentage of float is 2.91%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(FN) - Analyzing Fabrinet's Short Interest

AvalonBay Communities's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) short percent of float has fallen 12.16% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 2.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AvalonBay Communities Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730914213_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AvalonBay Communities has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AvalonBay Communities's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AvalonBay Communities's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(AVB) - Analyzing AvalonBay Communities's Short Interest

ROIC

Trading Halt: Halt status updated at 12:30:00 PM ET: Quotation Resumption: News and Resumption Times

TD Cowen analyst Joseph Giordano maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Buy and lowers the price target from $50 to $45.

TD Cowen Maintains Buy on Sensata Technologies, Lowers Price Target to $45

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Neutral and lowers the price target from $10 to $9.

QURE

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $9

WIIM

AMBA

INTC

LSCC

MRVL

NVDA

NXPI

QCOM

SLAB

Shares of companies in the broader semiconductor and chip sector are trading higher amid overall market strength following the US presidential election.

SMRT

SmartRent shares are trading lower after the company reported worse-than-expected Q3 financial results.

Montrose Environmental Group shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and cut its price target from $52 to $29.

Ero Copper shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, the company's co-founder and chairman retired.

TD Cowen analyst Jason Seidl maintains GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) with a Buy and raises the price target from $82 to $83.

TD Cowen Maintains Buy on GXO Logistics, Raises Price Target to $83

Goldman Sachs analyst George Tong maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Neutral and raises the price target from $45 to $51.

Goldman Sachs Maintains Neutral on UL Solutions, Raises Price Target to $51

TD Cowen analyst Joseph Giordano maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Hold and lowers the price target from $138 to $125.

TD Cowen Maintains Hold on Xylem, Lowers Price Target to $125

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a pri...

Buy Rating Affirmed for TScan Therapeutics Amidst Strong Pipeline Progress and Robust Financial Health

In a report released today, Peter Lawson from Barclays maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price target ...

Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from ...

Optimistic Outlook on TScan's TCR-T Therapies: A Comprehensive Buy Rating Review

In a report released today, David Nierengarten from Wedbush assigned a Buy rating to TScan Therapeutics (TCRX – Research Report), with a price targ...

TScan Therapeutics (TCRX) Gets a Buy from Wedbush

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price...

TScan Therapeutics (TCRX) Gets a Buy from Morgan Stanley

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price t...

Buy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy Space

TScan Therapeutics (TCRX) announced that preliminary results from the ALLOHA Phase 1 trial of TSC-100 and TSC-101, in patients with acute myeloid l...

TScan Therapeutics announces preliminary results from ALLOHA Phase 1 trial

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from ...

Buy Rating for TScan Therapeutics Driven by Promising Phase 1 Trial Results for TCR-T Cell Therapies

In a report released today, Gil Blum from Needham reiterated a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price target of $1...

Promising Phase I Results and Strong Safety Profile Reinforce Buy Rating for TScan Therapeutics

AMGN

TCRX

Earnings

Press Releases

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Opinion

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

Health Care

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

Management

TScan Therapeutics Announces Updates to its Board of Directors

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

CCCC

ONCY

PDSB

TSX:ONC

Abeona Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

TScan Therapeutics

TScan Therapeutics (TCRX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO